Table I. *Baseline characteristics of the patients enrolled in this study (n=76).*

Characteristic	Value
Age, years	
Median (range)	70 (36-83)
Gender, n (%)	
Male	39 (51.3)
Hb, g/dl	
Median (range)	9.55 (5.0-15.2)
Corrected calcium, n (%)	
<11.5 mg/dl	69 (90.8)
≥11.5 mg/dl	4 (5.3)
Missing data	3 (3.9)
Immunoglobulin subtype, n (%)	
IgG	37 (48.7)
IgA	20 (26.0)
IgM	1 (1.3)
IgD	1 (1.3)
Light chain only	16 (21.1)
Non-secretory	1 (1.3)
eGFR, n (%)	
≥40 ml/min/1.73 m^2	48 (63.2)
<40 ml/min/1.73 m^2	28 (36.8)
International Staging System classification, n (%)	
I	19 (25.0)
II	20 (26.3)
III	30 (39.5)
Missing data	7 (9.2)
Initial therapy, n (%)	
BD	66 (86.8)
BCD	9 (11.8)
MPB	1 (1.3)
Cytogenetics (available only), n (%)	
CCND1	7 (9.2)
FGFR3	2 (2.6)
MAF	0 (0)
P53	6 (7.9)
Chr 13 deletion	6 (7.9)
Observation period, months	
Median (range)	24 (1-97)

BCD: Cyclophosphamide plus bortezomib plus dexamethasone; BD: bortezomib plus dexamethasone; CCND1: cyclin D1; eGFR: estimated glomerular filtration rate; FGFR3: fibroblast growth factor receptor 3; MAF: v-maf musculoaponeurotic fibrosarcoma oncogene homolog; MPB: melphalan and prednisolone plus bortezomib.